Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Beijing SL Pharmaceutical Co Ltd
Accrued Liabilities
Beijing SL Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
|
Accrued Liabilities
¥36.6m
|
CAGR 3-Years
16%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
Beigene Ltd
HKEX:6160
|
Accrued Liabilities
¥4.9B
|
CAGR 3-Years
43%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
RemeGen Co Ltd
SSE:688331
|
Accrued Liabilities
¥327.2m
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
HKEX:6990
|
Accrued Liabilities
¥137.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing SL Pharmaceutical Co Ltd
Glance View
Beijing SL Pharmaceutical Co Ltd. is a notable player in the pharmaceutical sector, navigating the rigorous demands of healthcare with a focus on innovation and market responsiveness. Born from a deep understanding of the medical field, the company has carved a niche by focusing on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Among its specialties, Beijing SL Pharmaceutical is renowned for its expertise in producing complex chemicals and biologics, which are vital in treating various medical conditions ranging from cardiovascular diseases to neurological disorders. The company puts significant emphasis on research and development, ensuring that its product pipeline remains robust and poised for future growth. The commercial success of Beijing SL Pharmaceutical is largely driven by its keen adaptation to the dynamic healthcare needs both domestically and internationally. The company leverages its extensive distribution network and strategic partnerships with healthcare providers and institutions to ensure that its products reach patients efficiently. By maintaining a diverse product portfolio that caters to pressing medical needs, the company combines patient-centric strategies with astute business acumen to maintain steady revenue streams. Furthermore, its commitment to quality and safety standards reinforces trust among stakeholders, thereby enabling Beijing SL Pharmaceutical to thrive in a competitive landscape. As it continues to expand, the company remains vigilant in enhancing its technological capabilities and market reach, always with an eye on delivering value through health and wellness.
See Also
What is Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
36.6m
CNY
Based on the financial report for Sep 30, 2025, Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities amounts to 36.6m CNY.
What is Beijing SL Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
21%
Over the last year, the Accrued Liabilities growth was 12%. The average annual Accrued Liabilities growth rates for Beijing SL Pharmaceutical Co Ltd have been 16% over the past three years , 20% over the past five years , and 21% over the past ten years .